Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 11(7): e5137, 2019 Jul 15.
Article in English | MEDLINE | ID: mdl-31523566

ABSTRACT

One of the primary challenges of total hip arthroplasty (THA) is equalizing the limb lengths to re-establishing normal hip biomechanics. Post-operative leg length discrepancies (LLD) lead to patient dissatisfaction and are a main source of orthopedic malpractice cases. The aim of this case series was to document three cases of substantial LLD that were corrected during THA with the assistance of an imageless computer navigation system. Medical records were reviewed for history and radiographs were consulted. All patients in this series presented with complaints related to hip fractures and reported a significant lengthening of leg length following THA. No surgical complications of adverse events were reported. In these cases, imageless navigation provided intraoperative measurements of leg length which allowed for enhanced accuracy of component placement and improved outcomes following surgery.

2.
Clin Drug Investig ; 39(3): 233-239, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30652260

ABSTRACT

Androgenetic alopecia (AGA) is characterized by non-scarring follicle miniaturization. Despite the success of approved therapies, commonly reported side effects and the need for continual use has led to the investigation of alternative therapies. The aim of this paper is to critically review the success of off-label, topical monotherapies for treatment of AGA in men. A literature search was conducted to obtain randomized, controlled and blinded studies that investigated off-label, topical, monotherapies in male patients. Hair density, hair diameter and hair growth were used to evaluate treatment success. Fourteen off-label topical therapies were investigated among the 16 studies that met inclusion criteria. Nine off-label therapies were reported to produce a significantly greater improvement in hair restoration parameters (e.g. mean change from hair count and hair diameter) as compared to placebo (p < 0.05 for all treatments). In two studies, procyanidin oligomers exhibited greater efficacy over vehicle with response to mean change in hair density (hairs/cm2) (ps < 0.0001 at Week 24). In conclusion, prostaglandin analogs and polyphenols, such as latanoprost and procyanidin oligomers, can improve hair restoration parameters in male AGA patients, possibly through targeting mechanisms proposed in the etiology of AGA. The current evidence suggests short-term (24 weeks) use may provide benefit for hair loss patients; however, long-term efficacy and safety data are required.


Subject(s)
Alopecia/drug therapy , Hair/growth & development , Off-Label Use , Administration, Topical , Adult , Biflavonoids/administration & dosage , Catechin/administration & dosage , Humans , Latanoprost/administration & dosage , Proanthocyanidins/administration & dosage , Randomized Controlled Trials as Topic , Treatment Outcome
3.
J Hip Preserv Surg ; 6(4): 426-431, 2019 Dec.
Article in English | MEDLINE | ID: mdl-32015894

ABSTRACT

Periacetabular osteotomy (PAO) is an effective surgical treatment for hip dysplasia. The goal of PAO is to reorient the acetabulum to improve joint stability, lessen contact stresses and slow the development of hip arthrosis. During PAO, the acetabulum is repositioned to adequately cover the femoral head. PAO preserves the weight-bearing posterior column of the pelvis, maintains the acetabular blood supply and retains the hip abductor musculature. The surgical technique needed to perform PAO is technically demanding, with correct repositioning of the acetabulum the most important-and challenging-aspect of the procedure. Imageless navigation has proven useful in other technically challenging surgeries, although its use in PAO has not yet been investigated. We have modified the standard technique for PAO to include the use of an imageless navigation system to confirm acetabular fragment position following osteotomy. Here, we describe the surgical technique and discuss the potential of this modified technique to improve patient-related outcomes.

4.
Int J Dermatol ; 58(10): 1118-1129, 2019 Oct.
Article in English | MEDLINE | ID: mdl-30585300

ABSTRACT

Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophyte molds, and yeasts. This difficult-to-treat chronic infection has a tendency to relapse despite treatment. This paper aims to offer a global perspective on onychomycosis management from expert physicians from around the world. Overall, the majority of experts surveyed used systemic, topical, and combination treatments approved in their countries and monitored patients based on the product insert or government recommendations. Although the basics of treating onychomycosis were similar between countries, slight differences in onychomycosis management between countries were found. These differences were mainly due to different approaches to adjunctive therapy, rating the severity of disease and use of prophylaxis treatment. A global perspective on the treatment of onychomycosis provides a framework of success for the committed clinician with appreciation of how onychomycosis is managed worldwide.


Subject(s)
Antifungal Agents/therapeutic use , Foot Dermatoses/therapy , Global Health , Onychomycosis/therapy , Administration, Oral , Administration, Topical , Antifungal Agents/pharmacology , Arthrodermataceae/isolation & purification , Arthrodermataceae/pathogenicity , Clinical Trials as Topic , Comorbidity , Drug Interactions , Foot Dermatoses/epidemiology , Foot Dermatoses/microbiology , Global Burden of Disease , Humans , Low-Level Light Therapy/methods , Onychomycosis/epidemiology , Onychomycosis/microbiology , Photochemotherapy/methods , Prevalence , Recurrence , Tinea Pedis/drug therapy , Tinea Pedis/epidemiology , Treatment Outcome , Yeasts/isolation & purification , Yeasts/pathogenicity
5.
Skin Appendage Disord ; 4(4): 208-216, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30410887

ABSTRACT

PURPOSE: Onychomycosis is a nail disorder that is increasing in prevalence worldwide. The psychological and social limitations caused by onychomycosis can potentially undermine the work and social lives of those experiencing these negative effects. This review aimed to evaluate the randomized controlled trials (RCTs) available in the current literature on the impact onychomycosis has on quality of life (QoL). METHODS: A systematic review was performed using the databases PubMed, PsycINFO, Scopus, ClinicalTrials.gov, and Cochrane Library on July 18, 2017. Only RCTs with clinical effects described in English were included for review. RESULTS: Ten RCTs reported QoL outcomes for patients suffering from onychomycosis. Treatment satisfaction was statistically significant from baseline to end of treatment in 100.0% (4/4) measures which reported on satisfaction with treatment; mental health was also significant in 100.0% (3/3), symptoms index rating in 100.0% (2/2), symptom frequency in 75.0% (3/4), overall problems in 75.0% (3/4), functional activities in 75.0% (6/8), appearance problems in 66.7% (2/3), symptom distress in 57.1% (4/7), and stigma in 40.0% (2/5). The OnyCOE-tTM and the NailQoL were the most used common outcome measures to describe QoL. CONCLUSION: The study sanctions that onychomycosis physically and psychologically distresses patients' lives. Further research should include validated outcome measures to more effectively treat onychomycosis.

6.
Expert Rev Anti Infect Ther ; 16(12): 929-938, 2018 12.
Article in English | MEDLINE | ID: mdl-30411650

ABSTRACT

INTRODUCTION: Onychomycosis is a chronic fungal infection of the nail bed, matrix or plate. It accounts for roughly 50% of all nail disease. As the prevalence of onychomycosis is increasing, a critical review of diagnostic techniques and treatment options is required. Areas covered: This review discusses the current diagnostic techniques associated with diagnosing onychomycosis, such as microscopy, culture, periodic acid Schiff stain (PAS) and polymerase chain reaction (PCR). Oral and topical therapies are also discussed, as well as, the utility of device-based treatments and combination therapy. Expert commentary: Culture for the diagnosis of onychomycosis is the gold standard; however, PCR is more sensitive and should be considered. In general, topical treatments are recommended for mild to moderate disease and oral treatments should be considered for moderate to severe disease. Combination therapy and device-based treatments may enhance cure rates, further study is required.


Subject(s)
Antifungal Agents/administration & dosage , Onychomycosis/diagnosis , Administration, Oral , Administration, Topical , Foot Dermatoses/diagnosis , Foot Dermatoses/drug therapy , Foot Dermatoses/microbiology , Hand Dermatoses/diagnosis , Hand Dermatoses/drug therapy , Hand Dermatoses/microbiology , Humans , Microscopy , Onychomycosis/drug therapy , Onychomycosis/pathology , Polymerase Chain Reaction/methods , Severity of Illness Index
7.
Pediatr Dermatol ; 35(5): 552-559, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29943838

ABSTRACT

Onychomycosis is an uncommon condition in childhood, but prevalence in children is increasing worldwide.The objective was to review the efficacy and safety of systemic and topical antifungal agents to treat onychomycosis in children. Databases (Pubmed, OVID, Scopus, clinicaltrials.gov, Cochrane Library) were searched. Seven studies were selected for inclusion. Only one was a randomized controlled trial. In total, 208 children were administered antifungal agents for the treatment of onychomycosis. Four reports of mild adverse events were documented (1.9% of treated children), one of which discontinued treatment (0.5%). Limitations of this review are the lack of randomized controlled trials available in pediatric onychomycosis. These findings suggest that antifungal therapies used to treat onychomycosis in children are associated with a low incidence of adverse events. Current dosing regimens for antifungal drugs are effective and appear safe to use in children, notwithstanding that the Food and Drug Administration has not approved any of these agents for the treatment of onychomycosis in children. To our knowledge, this review is the most up-to-date, comprehensive summary of pediatric onychomycosis treatment.


Subject(s)
Antifungal Agents/therapeutic use , Onychomycosis/drug therapy , Antifungal Agents/adverse effects , Child , Female , Humans , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...